U.S. patent application number 10/305114 was filed with the patent office on 2003-07-03 for cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one n-vinylimidazole polymer or copolymer.
This patent application is currently assigned to L'OREAL. Invention is credited to Biatry, Bruno, Lheureux, Eric.
Application Number | 20030124161 10/305114 |
Document ID | / |
Family ID | 8869872 |
Filed Date | 2003-07-03 |
United States Patent
Application |
20030124161 |
Kind Code |
A1 |
Biatry, Bruno ; et
al. |
July 3, 2003 |
Cosmetic and/or dermatological use of a composition containing at
least one oxidation-sensitive hydrophilic active principle and at
least one N-vinylimidazole polymer or copolymer
Abstract
The invention relates to the use of a composition containing,
preferably in a physiologically acceptable medium comprising an
aqueous phase, at least one oxidation-sensitive hydrophilic active
principle selected from the group consisting of ascorbic acid and
its derivatives and at least one non-crosslinked N-vinylimidazole
polymer or copolymer, the active principle and the polymer or
copolymer both being present in the aqueous phase, for promoting
the synthesis of epidermal ceramides and/or for improving the
barrier function of the skin, among other uses.
Inventors: |
Biatry, Bruno; (Vincennes,
FR) ; Lheureux, Eric; (Montgeron, FR) |
Correspondence
Address: |
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA
VA
22314
US
|
Assignee: |
L'OREAL
Paris
FR
|
Family ID: |
8869872 |
Appl. No.: |
10/305114 |
Filed: |
November 27, 2002 |
Current U.S.
Class: |
424/401 ;
514/100; 514/458; 514/63 |
Current CPC
Class: |
A61K 8/676 20130101;
A61K 2800/522 20130101; A61P 17/16 20180101; A61P 43/00 20180101;
A61P 17/00 20180101; A61Q 19/08 20130101; A61Q 19/02 20130101; A61Q
5/08 20130101; A61K 8/817 20130101 |
Class at
Publication: |
424/401 ;
514/458; 514/63; 514/100 |
International
Class: |
A61K 031/695; A61K
031/665; A61K 031/375; A61K 007/06 |
Foreign Application Data
Date |
Code |
Application Number |
Nov 28, 2001 |
FR |
0115375 |
Claims
1. A method for promoting the synthesis of ceramides and/or
improving the barrier function of the skin, for maintaining and/or
improving the radiance of the complexion, for treating dry skin,
for moisturizing the skin, or for preventing and/or combating
roughness of the skin, comprising applying to the skin a
composition comprising, in a physiologically acceptable medium
comprising an aqueous phase, at least one oxidation-sensitive
hydrophilic active principle selected from the group consisting of
ascorbic acid and its derivatives and at least one non-crosslinked
N-vinylimidazole polymer or copolymer, the at least one active
principle and the at least one polymer or copolymer both being
present in the aqueous phase.
2. The method according to claim 1, wherein said method is for
maintaining and/or improving the radiance of the complexion.
3. The method according to claim 1, wherein said method is for
preventing and/or combating roughness of the skin.
4. The method according to claim 1, wherein said ascorbic acid
derivatives are selected from the group consisting of ascorbic acid
esters and ascorbic acid salts.
5. The method according to claim 1, wherein the hydrophilic active
principle is selected from the group consisting of
5,6-di-O-dimethylsilylascorbate, dl-.alpha.-tocopheryl dl-ascorbyl
phosphate potassium salt, magnesium ascorbyl phosphate and sodium
ascorbyl phosphate.
6. The method according to claim 1, wherein the hydrophilic active
principle is ascorbic acid.
7. The method according to claim 1, wherein the composition
comprises a non-crosslinked copolymer that is a combination of the
N-vinylimidazole with N-vinylpyrrolidone and/or N-vinylcaprolactam
subunits.
8. The method according to claim 1, wherein the composition
comprises a non-crosslinked copolymer that is an
N-vinylimidazole/N-vinylpyrrolidone copolymer.
9. The method according to claim 1, wherein the composition
comprises a non-crosslinked copolymer selected from the group
consisting of a vinylpyrrolidone/vinylimidazole (50/50) copolymer
having a weight-average molar mass of 1 200 000 and a
vinylpyrrolidone/vinylimidazole (50/50) copolymer having a
weight-average molar mass of 10 000.
10. The method according to claim 1, wherein the molar ratio of
N-vinylimidazole unit equivalent to the oxidation-sensitive
hydrophilic active principle is 0.004 to 16.
11. The method according to claim 10, wherein the molar ratio of
the N-vinylimidazole unit equivalent to the oxidation-sensitive
hydrophilic active principle varies between 0.01 and 1.
12. The method according to claim 1, wherein the polymer or
copolymer is present at a concentration of 0.1 to 5% by weight of
the aqueous phase.
13. The method according to claim 12, wherein the polymer or
copolymer is present at a concentration of 0.1 to 2% by weight of
the aqueous phase.
14. The method according to claim 1, wherein the polymer or
copolymer has a molar fraction of N-vinylimidazole units of 0.1 to
1.
15. The method according to claim 14, wherein the polymer or
copolymer has a molar fraction of N-vinylimidazole units of 0.4 to
0.9.
16. The method according to claim 1, wherein the composition
further comprises another agent in addition to the
oxidation-sensitive hydrophilic active principle, which agent acts
on the barrier function of the skin or which promotes moisturizing
of the skin and/or desquamating.
17. The method according to claim 16, the composition further
comprising an agent selected from the group consisting of
ceramides, sphingoid, lecithins, glycosphingolipids, phospholipids,
cholesterol and its derivatives, phytosterols, essential fatty
acids, 1,2-diacylglycerol, 4-chromanone, pentacyclic triterpenes,
petroleum jelly, lanolin, threalose and its derivatives, hyaluronic
acid and its derivatives, glycerol, pentanediol, sodium pidolate,
serine, xylitol, sodium lactate, glyceryl polyacrylate, ectoin and
its derivatives, chitosan, oligo- and polysaccharides, cyclic
carbonates, N-lauroylpyrrolidonecarboxylic acid,
N-.alpha.-benzoyl-L-arginine, DHEA and steroid derivatives, and
vitamin D and its derivatives.
18. The method according to claim 16, the composition further
comprising an agent selected from the group consisting of
.beta.-hydroxy acids; .alpha.-hydroxy acids; urea; gentisic acid;
oligofucoses; cinnamic acid; Saphora japonica extract; resveratrol;
EDTA; N-acyl-N,N',N'-ethylenediami- netriacetic acid;
aminosulphonic compounds; 2-oxothiazolidine-4-carboxylic acid
(procysteine) derivatives; derivatives of .alpha.-amino acids of
glycine; honey; and sugar derivatives.
19. The method of claim 1, for promoting the synthesis of ceramides
and/or improving the barrier function of the skin.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to the cosmetic and/or
dermatological use of a composition comprising at least one
oxidation-sensitive hydrophilic active principle and at least one
N-vinylimidazole polymer or copolymer in a physiologically
acceptable medium comprising an aqueous phase.
BACKGROUND OF THE INVENTION
[0002] It is known to introduce, into cosmetic compositions,
various active principles intended to contribute specific
treatments to the skin and/or hair. However, some of these active
principles exhibit the disadvantage of being unstable in an aqueous
medium and of easily decomposing on contact with water, in
particular because of oxidation phenomena. They thus rapidly lose
their activity over time and this instability conflicts with the
desired effectiveness.
[0003] Attempts have thus been made for a long time to formulate
ascorbic acid or vitamin C because of its numerous beneficial
properties. In particular, ascorbic acid stimulates the synthesis
of the connective tissue and in particular of collagen, strengthens
the defences of the cutaneous tissue against external attacks, such
as ultraviolet radiation and pollution, compensates for vitamin E
deficiency of the skin, depigments the skin and has a role in
combating free radicals. These last two properties make it an
excellent candidate as cosmetic or dermatological active principle
for combating ageing of the skin or for preventing ageing of the
skin. Unfortunately, because of its chemical structure (of
.alpha.-ketolactone), ascorbic acid is highly sensitive to certain
environmental parameters and in particular to oxidation phenomena.
There thus ensues rapid decomposition of formulated ascorbic acid
in the presence of these parameters and in particular in the
presence of oxygen, light or metal ions, as a function of the
temperature or under certain pH conditions (Pharm. Acta. Helv.,
1969, 44, 611-667; STP Pharma, 1985, 4, 281-286).
[0004] Several solutions have thus been envisaged in the prior art
for reducing and/or slowing down the decomposition of ascorbic
acid.
[0005] Provision has thus been made to use ascorbic acid in the
form of a chemical derivative (magnesium ascorbyl phosphate or
esters of fatty acids and ascorbic acid), but the bioavailability
of these derivatives is very low (J. Am. Acad. Dermatol., 1996, 34,
29-33).
[0006] The instability of ascorbic acid with respect to oxygen can
be improved by using specific packagings, such as twin compartments
under an inert atmosphere, as disclosed in Patent U.S. Pat. No.
5,935,584, or alternatively by the use of two-phase emulsions, one
phase of which is composed of a dry powder comprising ascorbic acid
and the second phase of which is a liquid phase. The mixing of the
two phases has to be carried out at the time of use (WO 98/43598).
These solutions have disadvantages with regard to the cost and the
complexity of the manufacturing operations and significant
restrictions with regard to use.
[0007] Another solution provided in the prior art consists in using
a high concentration of glycols or polyols in order to reduce the
solubility of oxygen in the formulation, thus protecting the
ascorbic acid (WO 96/24325, EP 0 755 674, U.S. Pat. No. 5,981,578).
The polyols can optionally be incorporated in liposomes, as
disclosed in Patent U.S. Pat. No. 6,020,367. However, these
solutions exhibit the disadvantage of resulting in sticky
formulations, the cosmetic quality of which is difficult to
improve. Furthermore, the presence of a high concentration of these
compounds can lead to phenomena of irritation.
[0008] Ascorbic acid can also be formulated in anhydrous media,
such as silicones (U.S. Pat. No. 6,194,452), which are capable of
creating an anhydrous barrier around ascorbic acid. A major
disadvantage of such solutions results from the lack of freshness
on application.
[0009] The need thus remains for a composition employable in
particular in the cosmetics field, in which a hydrophilic active
principle which is unstable in an oxidizing medium is stabilized,
which is comfortable on application, which does not lead to any
skin irritation after application and which is compatible with the
constraints of an industrial implementation of its manufacturing
process.
[0010] Ascorbic acid is capable of improving the lipid profile of
reconstructed epidermides by modifying lipogenesis and causes in
particular an increase in the synthesis of ceramides (J. Invest.
Dermatol., 109, 1997, p. 348-355). In the same way, this effect has
also been demonstrated for ascorbic acid derivatives, such as
magnesium ascorbyl phosphate or ascorbyl glucoside. Studies have
also shown that the barrier function of reconstructed epidermides
is improved after treatment with ascorbic acid (EP-1 145 706, EP-1
145 710).
[0011] The advantage of using these derivatives in order to
maintain and to strengthen the integrity of the lipids of the skin,
and thus of overcoming problems of moisturizing, is then
understood.
[0012] In addition to this activity with regard to the synthesis of
lipids, a prodifferentiating effect on keratinocytes of ascorbic
acid has recently been demonstrated (Histochem. Cell. Biol.,
116(6), 2001, p.287-297). This effect has the consequence of
overcoming the detrimental change in this mechanism for the
differentiation of keratinocytes which results in an accumulation
of squamae at the surface of the skin. This phenomenon modifies the
interactions between the surface of the skin and light and is
responsible for a faded and rough appearance of the skin.
[0013] Ascorbic acid and its derivatives can therefore
advantageously be used to combat a faded complexion and to maintain
the radiance of the skin.
OBJECTS OF THE INVENTION
[0014] One object of the present invention is to provide a
composition comprising an oxidation-sensitive active principle
preferably selected from the group consisting of ascorbic acid and
its derivatives, which exhibits good cosmetic properties, both with
regard to touch and with regard to tolerance, the preservation of
which over time does not require specific precautions, and which
retains the activity of the said active principle in improving the
synthesis of ceramides and the barrier function of the skin and in
improving the differentiation of keratinocytes, among other
benefits and attributes.
DETAILED DESCRIPTION OF THE INVENTION
[0015] The inventors have discovered that the use of
non-crosslinked N-vinylimidazole polymers or copolymers in
compositions in which the aqueous phase includes an
oxidation-sensitive active principle, such as ascorbic acid or one
of its derivatives, makes it possible to achieve the abovementioned
aim.
[0016] In the prior art, some compounds having an imidazole
structure have been disclosed for their stabilizing properties.
Thus, in Patent Application EP 0 586 106, several imidazole-based
molecules are used to stabilize certain retinoids against chemical
decomposition. Furthermore, polymeric emulsifiers composed of
N-vinylimidazole, of alkyl acrylates and of vinyl acetates are
disclosed in Patent U.S. Pat. No. 4,057,622. They are used for the
purpose of replacing known emulsifiers in order to overcome their
disadvantages, in particular with regard to smell, and to stabilize
water-in-oil emulsions. Finally, N-vinylimidazole/N-vinylcaprol-
actam/N-vinylpyrrolidone copolymers are disclosed in Patent U.S.
Pat. No. 6,191,188. They are used in the manufacture of
hair-strengthening compositions.
[0017] To the knowledge of the inventors, polymers or copolymers
comprising N-vinylimidazole units have never been used in
combination with hydrophilic active principles sensitive to
decomposition by oxidation for the purpose of improving their
stability in an aqueous medium. This is true in particular in the
case of ascorbic acid.
[0018] An embodiment of the present invention is therefore the
cosmetic and/or dermatological use, for promoting the synthesis of
ceramides and/or improving the barrier function of the skin, of a
composition comprising, in a physiologically acceptable medium
comprising an aqueous phase, at least one oxidation-sensitive
hydrophilic active principle selected from the group consisting of
ascorbic acid and its derivatives and at least one non-crosslinked
N-vinylimidazole polymer or copolymer, the active principle and the
polymer or copolymer both being in the aqueous phase. The polymer
or copolymer is preferably present in an amount sufficient to
stabilize the said oxidation-sensitive hydrophilic active
principle.
[0019] Another embodiment of the present invention is the cosmetic
and/or dermatological use, for combating roughness of the skin
and/or maintaining and/or improving the radiance of the complexion,
of a composition comprising, in a physiologically acceptable medium
comprising an aqueous phase, at least one oxidation-sensitive
hydrophilic active principle selected from the group consisting of
ascorbic acid and its derivatives and at least one non-crosslinked
N-vinylimidazole polymer or copolymer, the active principle and the
polymer or copolymer both being in the aqueous phase.
[0020] Another embodiment of the invention is the use of a
combination composed of at least one oxidation-sensitive
hydrophilic active principle selected from the group consisting of
ascorbic acid and its derivatives and of at least one
non-crosslinked N-vinylimidazole polymer or copolymer in the
aqueous phase of a cosmetic composition as agent for promoting the
synthesis of ceramides and/or improving the barrier function of the
skin.
[0021] Another embodiment of the invention is the use of a
combination composed of at least one oxidation-sensitive
hydrophilic active principle selected from the group consisting of
ascorbic acid and its derivatives and of at least one
non-crosslinked N-vinylimidazole polymer or copolymer in the
aqueous phase of a cosmetic composition as agent for combating
roughness of the skin and/or maintaining and/or improving the
radiance of the complexion.
[0022] According to the invention, the term "hydrophilic active
principle" is understood to mean a compound having a solubility in
water of at least 0.25% at ambient temperature (25.degree. C.).
[0023] According to the invention, the term "oxidation-sensitive
hydrophilic active principle" is understood to mean any active
principle of natural or synthetic origin capable of undergoing
decomposition by an oxidation mechanism. This oxidation phenomenon
can have several causes, in particular the presence of oxygen, of
light or of metal ions, a high temperature or certain pH
conditions.
[0024] Mention may be made, by way of example and without implied
limitation, of: ascorbic acid and its derivatives, such as salts or
esters thereof, particularly the 5,6-di-O-dimethylsilylascorbate
(sold by Exsymol under the reference PRO-AA), the potassium salt of
dl-.alpha.-tocopheryl dl-ascorbyl phosphate (sold by Senju
Pharmaceutical under the reference SEPIVITAL EPC), magnesium
ascorbyl phosphate or sodium ascorbyl phosphate (sold by Roche
under the reference Stay-C 50). Preferred principles meet the
hydrophilic and oxidation sensitive descriptions above and in
addition bring about at least one of the effects described above
such as promoting the synthesis of ceramides, etc.
[0025] In a particularly advantageous aspect, the
oxidation-sensitive hydrophilic active principle is ascorbic
acid.
[0026] The principle is preferably present in an amount sufficient
to bring about its intended effect, such as, for example, in an
amount of 0.5, 1, 5, 25, etc. grams per 100 g of composition.
[0027] According to the invention, the term "non-crosslinked
N-vinylimidazole polymer or copolymer" is understood to mean any
polymer comprising N-vinylimidazole units and not comprising a
crosslinking agent. Copolymers suitable for the implementation of
the invention are copolymers combining N-vinylimidazole with
N-vinylpyrrolidone and/or N-vinylcaprolactam subunits.
[0028] In an advantageous aspect of the invention, the copolymer
has a molar fraction of N-vinylimidazole units of between 0.1 and
1, more preferably between 0.4 and 0.9, inclusive.
[0029] According to an advantageous aspect of the invention, the
molar ratio of the N-vinylimidazole unit equivalent to the
oxidation-sensitive hydrophilic active principle varies between
0.004 and 16 and preferably between 0.01 and 1, inclusive.
[0030] Use will preferably be made of an
N-vinylimidazole/N-vinylpyrrolido- ne copolymer.
[0031] The weight-average molar mass of the N-vinylimidazole
polymers will advantageously be between 1000 and 1.times.10.sup.7
and preferably between 5000 and 5.times.10.sup.6.
[0032] Use may be made, to this end, of the
vinylpyrrolidone/vinylimidazol- e (50/50) copolymer having a
weight-average molar mass of 1200000 sold under the reference
LUVITEC VPI 55K72W by BASF or the vinylpyrrolidone/vinylimidazole
(50/50) copolymer having a weight-average molar mass of 10000 sold
under the reference LUVITEC VPI 55K18P by BASF.
[0033] The at least one polymer or copolymer is preferably present
in the composition according to the invention in an amount
sufficient to produce the desired effect, that is to say in an
amount sufficient to stabilize the oxidation-sensitive hydrophilic
active principle. Preferably, the copolymer is present at a
concentration of between 0.1 and 5% by weight with respect to the
total weight of the aqueous phase and more particularly at a
concentration of between 0.1 and 2% by weight with respect to the
total weight of the aqueous phase. The amount preferably is a
stabilizing amount that delays or stops decomposition of the active
principle when tested at 45.degree. C. for two months.
[0034] The compositions used according to the invention are
preferably intended for topical application to the skin and/or its
superficial body growths and therefore comprise a physiologically
acceptable medium, that is to say a medium compatible with
cutaneous tissues, such as the skin, scalp, eyelashes, eyebrows,
hair, nails and mucous membranes. This physiologically acceptable
medium comprises an aqueous phase and optionally a physiologically
acceptable organic solvent chosen, for example, from lower alcohols
comprising from 1 to 8 carbon atoms and in particular from 1 to 6
carbon atoms, such as ethanol, isopropanol, propanol or butanol;
polyethylene glycols having from 6 to 80 ethylene oxide units; or
polyols, such as propylene glycol, isoprene glycol, butylene
glycol, glycerol or sorbitol.
[0035] When the physiologically acceptable medium is an aqueous
medium, it generally preferably has a pH which is compatible with
the skin, preferably ranging from 3 to 9 and better still from 3.5
to 7.5.
[0036] The compositions according to the invention can be provided
in any form, including any pharmaceutical dosage form used
conventionally for topical application and in particular in the
form of aqueous or aqueous/alcoholic solutions, of oil-in-water
(O/W) or water-in-oil (W/O) or multiple (triple: W/O/W or O/W/O)
emulsions, of aqueous gels or of dispersions of a fatty phase in an
aqueous phase using spherules, it being possible for these
spherules to be polymeric nanoparticles, such as nanospheres and
nanocapsules, or lipid vesicles of ionic and/or nonionic type
(liposomes, niosomes or oleosomes). These compositions are prepared
according to the usual methods.
[0037] In addition, the compositions used according to the
invention can be more or less fluid and can have the appearance of
a white or coloured cream, of an ointment, of a milk, of a lotion,
of a serum, of a paste or of a foam. They can optionally be applied
to the skin in the form of an aerosol. They can also be provided in
a solid form, for example in the form of a stick.
[0038] When the composition according to the invention comprises an
oily phase, the latter preferably comprises at least one oil. It
can additionally comprise other fatty substances.
[0039] Mention may be made, as oils which can be used in the
composition of the invention, of, for example:
[0040] hydrocarbonaceous oils of animal origin, such as
perhydrosqualene;
[0041] hydrocarbonaceous oils of vegetable origin, such as liquid
triglycerides of fatty acids comprising from 4 to 10 carbon atoms,
such as triglycerides of heptanoic acid or octanoic acid, or
alternatively, for example, sunflower, maize, soybean, gourd, grape
seed, sesame, hazelnut, apricot, macadamia, arara, castor or
avocado oils, triglycerides of caprylic/capric acids, such as those
sold by Starineries Dubois or those sold under the names Miglyol
810, 812 and 818 by Dynamit Nobel, jojoba oil, or karite butter
oil;
[0042] synthetic esters and ethers, in particular of fatty acids,
such as the oils of formulae R.sup.1COOR.sup.2 and R.sup.1OR.sup.2
in which R.sup.1 represents the residue of a fatty acid comprising
from 8 to 29 carbon atoms and R.sup.2 represents a branched or
unbranched hydrocarbonaceous chain comprising from 3 to 30 carbon
atoms, such as, for example, purcellin oil, isononyl isononanoate,
isopropyl myristate, 2-ethylhexyl palmitate, 2-octyldodecyl
stearate, 2-octyldodecyl erucate or isostearyl isostearate;
hydroxylated esters, such as isostearyl lactate, octyl
hydroxystearate, octyldodecyl hydroxystearate, diisostearyl malate,
triisocetyl citrate or heptanoates, octanoates or decanoates of
fatty alcohols; polyol esters, such as propylene glycol
dioctanoate, neopentyl glycol diheptanoate and diethylene glycol
diisononanoate; and pentaerythritol esters, such as pentaerythrityl
tetraisostearate;
[0043] linear or branched hydrocarbons of mineral or synthetic
origin, such as volatile or nonvolatile liquid paraffins and their
derivatives, liquid petrolatum, polydecenes or hydrogenated
polyisobutene, such as parleam oil;
[0044] fatty alcohols having from 8 to 26 carbon atoms, such as
cetyl alcohol, stearyl alcohol and their mixture (cetearyl
alcohol), octyldodecanol, 2-butyloctanol, 2-hexyldecanol,
2-undecylpentadecanol, oleyl alcohol or linoleyl alcohol;
[0045] partially hydrocarbon-comprising and/or silicone-comprising
fluorinated oils, such as those disclosed in the document
JP-A-2-295912;
[0046] silicone oils, such as volatile or nonvolatile
polymethylsiloxanes (PDMS) comprising a linear or cyclic silicone
chain which are liquid or pasty at ambient temperature, in
particular cyclopolydimethylsiloxanes (cyclomethicones), such as
cyclohexasiloxane; polydimethylsiloxanes comprising pendent alkyl,
alkoxy or phenyl groups or alkyl, alkoxy or phenyl groups at the
end of the silicone chain, which groups have from 2 to 24 carbon
atoms; or phenylated silicones, such as phenyl trimethicones,
phenyl dimethicones, phenyltrimethylsiloxydiphenylsiloxane- s,
diphenyl dimethicones, diphenylmethyldiphenyltrisiloxanes,
(2-phenylethyl)trimethylsiloxysilicates and
polymethylphenylsiloxanes;
[0047] their mixtures.
[0048] The term "hydrocarbonaceous oil" is understood to mean, in
the list of the oils mentioned above, any oil predominantly
comprising carbon and hydrogen atoms and optionally ester, ether,
fluorinated, carboxylic acid and/or alcohol groups.
[0049] The other fatty substances which can be present in the oily
phase are, for example, fatty acids comprising from 8 to 30 carbon
atoms, such as stearic acid, lauric acid, palmitic acid and oleic
acid; waxes, such as lanolin, beeswax, carnauba or candelilla wax,
paraffin or lignite waxes or microcrystalline waxes, ceresin or
ozokerite, or synthetic waxes, such as polyethylene waxes or
Fischer-Tropsch waxes; silicone resins, such as trifluoromethyl
C.sub.1-4 alkyl dimethicone and trifluoropropyl dimethicone; and
silicone elastomers, such as the products sold under the names
"KSG" by Shin-Etsu, under the names "Trefil", "BY29" or "EPSX" by
Dow Corning or under the names "Gransil" by Grant Industries.
[0050] These fatty substances can be chosen in a way varied by a
person skilled in the art in order to prepare a composition having
the desired properties, for example of consistency or of texture,
without undue hardship.
[0051] According to a specific embodiment of the invention, the
composition according to the invention is a water-in-oil (W/O) or
oil-in-water (O/W) emulsion. The proportion of the oily phase in
the emulsion may preferably range from 5 to 80% by weight and
preferably from 5 to 50% by weight with respect to the total weight
of the composition.
[0052] The emulsions generally comprise at least one emulsifier
selected from the group consisting of amphoteric, anionic, cationic
or nonionic emulsifiers, used alone or as a mixture, and optionally
a coemulsifier. The emulsifiers are preferably chosen according to
the emulsion to be obtained (W/O or O/W). The emulsifier and the
coemulsifier are generally preferably present in the composition in
a proportion ranging from 0.3 to 30% by weight and preferably from
0.5 to 20% by weight with respect to the total weight of the
composition.
[0053] Mention may be made, for the W/O emulsions, for example, as
emulsifiers, of dimethicone copolyols, such as the mixture of
cyclomethicone and of dimethicone copolyol sold under the name "DC
5225 C" by Dow Corning, and alkyl dimethicone copolyols, such as
the laurylmethicone copolyol sold under the name "Dow Corning 5200
Formulation Aid" by Dow Corning and the cetyl dimethicone copolyol
sold under the name Abil EM 90.sup.R by Goldschmidt. Use may also
be made, as surfactant of W/O emulsions, of a crosslinked solid
organopolysiloxane elastomer comprising at least one oxyalkylenated
group, such as those obtained according to the procedure of
Examples 3, 4 and 8 of the document U.S. Pat. No. 5,412,004 and the
examples of the document U.S. Pat. No. 5,811,487, in particular the
product of Example 3 (synthetic example) of Patent U.S. Pat. No.
5,412,004, and such as that sold under the reference KSG 21 by Shin
Etsu. Use may also be made, as emulsifier, of a polyolefin-derived
oligomer or polymer comprising a succinic ending; the latter is
preferably a polyolefin comprising an esterified or amidated
succinic ending or a salt of such a polyolefin and in particular
polyisobutylene comprising an esterified or amidated succinic
ending such as the products sold under the names L5603 and L2721
and OS131769 by Lubrizol.
[0054] Mention may be made, for the O/W emulsions, for example, as
emulsifiers, of nonionic emulsifiers, such as esters of fatty acids
and of glycerol which are oxyalkylenated (more particularly
polyoxyethylenated); esters of fatty acids and of sorbitan which
are oxyalkylenated; esters of fatty acids which are oxyalkylenated
(oxyethylenated and/or oxypropylenated); ethers of fatty alcohols
which are oxyethylenated (oxyethylenated and/or oxypropylenated);
sugar esters, such as sucrose stearate; and their mixtures, such as
the mixture of glyceryl stearate and of PEG-40 stearate.
[0055] The composition of the invention can also comprise adjuvants
known in the cosmetics or dermatological field, such as hydrophilic
or lipophilic gelling agents, preservatives, solvents, fragrances,
fillers, UV screening agents, bactericides, odour absorbers,
colouring materials, plant extracts or salts. The amounts of these
various adjuvants are those used in the field under consideration,
for example from 0.01 to 20% of the total weight of the
composition. These adjuvants, depending on their nature, can be
introduced into the fatty phase, into the aqueous phase and/or into
the lipid spherules.
[0056] Mention may be made, as fillers which can be used in the
composition of the invention, for example, of pigments, silica
powder; talc; particles of polyamide and in particular those sold
under the name Orgasol by Atochem; polyethylene powders;
microspheres based on acrylic copolymers, such as those made of
ethylene glycol dimethacrylate/lauryl methacrylate copolymer which
are sold by Dow Coming under the name Polytrap; expanded powders,
such as hollow microspheres and in particular the microspheres sold
under the name Expancel by Kemanord Plast or under the name
Micropearl F 80 ED by Matsumoto; silicone resin microbeads, such as
those sold under the name Tospearl by Toshiba Silicone; and their
mixtures. These fillers can be present in amounts ranging from 0 to
20% by weight and preferably from 1 to 10% by weight with respect
to the total weight of the composition.
[0057] According to a preferred embodiment, the compositions in
accordance with the invention can additionally comprise at least
one organic photoprotective agent and/or at least one inorganic
photoprotective agent which is active in the UV-A and/or UV-B
regions (absorbers), and which are soluble in water or in fats or
else are insoluble in the cosmetic solvents commonly used.
[0058] The organic photoprotective agents may be chosen in
particular from anthranilates; cinnamic derivatives;
dibenzoylmethane derivatives; salicylic derivatives; camphor
derivatives; triazine derivatives, such as those disclosed in
Patent Applications U.S. Pat. No. 4,367,390, EP 863 145, EP 517
104, EP 570 838, EP 796 851, EP 775 698, EP 878 469, EP 933 376, EP
507 691, EP 507 692, EP 790 243 and EP 944 624; benzophenone
derivatives; .beta.,.beta.-diphenylacrylate derivatives;
benzotriazole derivatives; benzalmalonate derivatives;
benzimidazole derivatives; imidazolines; bisbenzoazolyl derivatives
as disclosed in Patents EP 669 323 and U.S. Pat. No. 2,463,264;
p-aminobenzoic acid (PABA) derivatives;
methylenebis(hydroxyphenylbenzotriazole) derivatives as disclosed
in Applications U.S. Pat. Nos. 5,237,071, 5,166,355, GB 2 303 549,
DE 197 26 184 and EP 893 119; screening polymers and screening
silicones, such as those disclosed in particular in Application WO
93/04665; dimers derived from .alpha.-alkylstyrene, such as those
disclosed in Patent Application DE 198 55 649; 4,4-diarylbutadienes
as disclosed in Applications EP 0 967 200, DE 197 46 654, DE 197 55
649, EP-A-1 008 586, EP 1 133 980 and EP 133 981; and their
mixtures.
[0059] By way of illustration, mention may be made, as
photoprotective agents which are active in the UV-A and/or UV-B
regions, denoted below under their INCI names, of:
[0060] p-aminobenzoic acid (PABA) derivatives, in particular PABA,
ethyl PABA, ethyl dihydroxypropyl PABA, ethylhexyl dimethyl PABA
(sold in particular under the name "Escalol 507" by ISP), glyceryl
PABA or PEG-25 PABA (sold under the name "Uvinul P25" by BASF),
[0061] salicylic derivatives, in particular homosalate (sold under
the name "Eusolex HMS" by Rona/EM Industries), ethylhexyl
salicylate (sold under the name "Neo Heliopan OS" by Haarmann and
Reimer), dipropylene glycol salicylate (sold under the name
"Dipsal" by Scher), or TEA salicylate (sold under the name "Neo
Heliopan TS" by Haarmann and Reimer),
[0062] dibenzoylmethane derivatives, in particular butyl
methoxydibenzoylmethane (sold in particular under the trade name
"Parsol 1789" by Hoffmmann-LaRoche), or isopropyl
dibenzoylmethane,
[0063] cinnamic derivatives, in particular ethylhexyl
methoxycinnamate (sold in particular under the trade name "Parsol
MCX" by Hoffmmann-LaRoche), isopropyl methoxycinnamate, isoamyl
methoxycinnamate (sold under the trade name "Neo Heliopan E 1000"
by Haarmann and Reimer), cinoxate, DEA methoxycinnamate,
diisopropyl methyl cinnamate, or glyceryl ethylhexanoate
dimethoxycinnamate,
[0064] .beta.,.beta.-diphenylacrylate derivatives, in particular
octocrylene (sold in particular under the trade name "Uvinul N539"
by BASF) or etocrylene (sold in particular under the trade name
"Uvinul N35" by BASF),
[0065] benzophenone, in particular benzophenone-1 (sold under the
trade name "Uvinul 400" by BASF), benzophenone-2 (sold under the
trade name "Uvinul D50" by BASF), benzophenone-3 or oxybenzone
(sold under the trade name "Uvinul M40" by BASF), benzophenone-4
(sold under the trade name "Uvinul MS40" by BASF), benzophenone-5,
benzophenone-6 (sold under the trade name "Helisorb 11" by
Norquay), benzophenone-8 (sold under the trade name "Spectra-Sorb
UV-24" by American Cyanamid), benzophenone-9 (sold under the trade
name "Uvinul DS-49" by BASF), benzophenone-12, or n-hexyl
2-(4-diethylamino-2-hydroxybenzoyl)benzoate,
[0066] benzylidene camphor derivatives, in particular 3-benzylidene
camphor (manufactured under the name "Mexoryl SD" by Chimex),
4-methylbenzylidene camphor (sold under the name "Eusolex 6300" by
Merck), benzylidene camphor sulphonic acid (manufactured under the
name "Mexoryl SL" by Chimex), camphor benzalkonium methosulphate
(manufactured under the name "Mexoryl SO" by Chimex),
terephthalylidene dicamphor sulphonic acid (manufactured under the
name "Mexoryl SX" by Chimex), or polyacrylamidomethyl benzylidene
camphor (manufactured under the name "Mesoryl SW" by Chimex),
[0067] benzimidazole derivatives, in particular phenylbenzimidazole
sulphonic acid (sold in particular under the trade name "Eusolex
232" by Merck), or disodium phenyl dibenzimidazole tetrasulphonate
(sold under the trade name "Neo Heliopan AP" by Haarmann and
Reimer),
[0068] triazine derivatives, in particular anisotriazine (sold
under the trade name "Tinosorb S" by Ciba Specialty Chemicals),
ethylhexyl triazone (sold in particular under the trade name
"Uvinul T150" by BASF), diethylhexyl butamido triazone (sold under
the trade name "Uvasorb HEB" by Sigma 3V) or 2,4,6-tris(diisobutyl
4'-amino-benzalmalonate)-s-triazine- ,
[0069] benzotriazole derivatives, in particular drometrizole
trisiloxane (sold under the name "Silatrizole" by Rhodia Chimie) or
methylene bisbenzotriazolyl tetramethylbutylphenol (sold in the
solid form under the trade name "Mixxim BB/100" by Fairmount
Chemical or in the micronized form in aqueous dispersion under the
trade name "Tinosorb M" by Ciba Specialty Chemicals),
[0070] anthranilic derivatives, in particular menthyl anthranilate
(sold under the trade name "Neo Heliopan MA" by Haarmann and
Reimer),
[0071] imidazoline derivatives, in particular ethylhexyl
dimethoxybenzylidene dioxoimidazoline propionate,
[0072] benzalmalonate derivatives, in particular polyorganosiloxane
comprising benzalmalonate functional groups (sold under the trade
name "Parsol SLX" by Hoffmmann-LaRoche),
[0073] 4,4-diarylbutadiene derivatives, in particular
1,1'-dicarboxy (2,2'-dimethyl-propyl)-4,4-diphenylbutadiene,
[0074] and their mixtures.
[0075] The organic photoprotective agents which are more
particularly preferred are selected from the group consisting of
ethylhexyl salicylate, ethylhexyl methoxycinnamate, octocrylene,
phenylbenzimidazole sulphonic acid, benzophenone-3, benzophenone-4,
benzophenone-5, 4-methylbenzylidene camphor, terephthalylidene
dicamphor sulphonic acid, disodium phenyl dibenzimidazole
tetrasulphonate, 2,4,6-tris(diisobutyl
4'-aminobenzalmalonate)-s-triazine, anisotriazine, ethylhexyl
triazone, diethylhexyl butamido triazone, methylene
bisbenzotriazolyl tetramethylbutylphenol, drometrizole trisiloxane,
1,1'-dicarboxy (2,2'-dimethylpropyl)-4,4-diphenylbutadiene, and
their mixtures.
[0076] The inorganic photoprotective agents may be selected from
the group consisting of pigments or alternatively nanopigments
(mean size of the primary particles: generally between 5 nm and 100
nm, preferably between 10 nm and 50 nm) formed from coated or
uncoated metal oxides, such as, for example, titanium oxide
(amorphous or crystalline in the rutile and/or anatase form), iron
oxide, zinc oxide, zirconium oxide or cerium oxide nanopigments,
which are all UV photoprotective agents well known per se.
Conventional coating agents are, furthermore, alumina and/or
aluminium stearate. Such nanopigments formed from coated or
uncoated metal oxides are disclosed in particular in Patent
Applications EP 518 772 and EP 518 773.
[0077] The photoprotective agents are generally present in the
compositions according to the invention in proportions ranging from
0.1 to 20% by weight with respect to the total weight of the
composition and preferably ranging from 0.2 to 15% by weight with
respect to the total weight of the composition.
[0078] In another advantageous aspect of the invention, the
composition used can additionally comprise at least one other
active principle in addition to the principle described above which
acts on the barrier function of the skin or which promotes
moisturizing of the skin and/or one desquamating agent.
[0079] The term "desquamating agent" is understood to mean any
compound capable of acting:
[0080] either directly on desquamation by promoting exfoliation,
such as .beta.-hydroxy acids, in particular salicylic acid and its
derivatives (including 5-(n-octanoyl)salicylic acid);
.alpha.-hydroxy acids, such as glycolic acid, citric acid, lactic
acid, tartaric acid, malic acid or mandelic acid; urea; gentisic
acid; oligofucoses; cinnamic acid; Saphora japonica extract; or
resveratrol;
[0081] or on the enzymes involved in desquamation or decomposition
of the corneodesmosomes, such as glycosidases, stratum corneum
chymotryptic enzyme (SCCE) or indeed even other proteases (trypsin,
chymotrypsin-like). Mention may be made of agents which chelate
inorganic salts: EDTA; N-acyl-N,N',N'-ethylene-diaminetriacetic
acid; aminosulphonic compounds and in particular
N-(2-hydroxyethyl)piperazine-N- '-2-ethanesulphonic acid (HEPES);
2-oxothiazolidine-4-carboxylic acid (procysteine) derivatives;
derivatives of .alpha.-amino acids of glycine type (as disclosed in
EP-0 852 949, and sodium methylglycinediacetate, sold by BASF under
the trade name Trilon M ); honey; or sugar derivatives, such as
O-octanoyl-6-D-maltose and N-acetylglucosamine.
[0082] Mention may be made, among the active principles which act
on the barrier function of the skin or which promote moisturizing
of the skin, of, for example:
[0083] either compounds which act on the barrier function, for the
purpose of keeping the stratum corneum moisturized, or occlusive
compounds, in particular ceramides, sphingoid-based compounds,
lecithins, glycosphingolipids, phospholipids, cholesterol and its
derivatives, phytosterols (stigmasterol, .beta.-sitosterol or
campesterol), essential fatty acids, 1,2-diacylglycerol,
4-chromanone, pentacyclic triterpenes, such as ursolic acid,
petroleum jelly and lanolin;
[0084] or compounds which directly increase the water content of
the stratum corneum, such as threalose and its derivatives,
hyaluronic acid and its derivatives, glycerol, pentanediol, sodium
pidolate, serine, xylitol, sodium lactate, glyceryl polyacrylate,
ectoin and its derivatives, chitosan, oligo- and polysaccharides,
cyclic carbonates, N-lauroylpyrrolidonecarboxylic acid and
N-.alpha.-benzoyl-L-arginine;
[0085] or compounds which activate the sebaceous glands, such as
steroid derivatives (including DHEA) and vitamin D and its
derivatives.
[0086] The composition according to the invention can be applied to
the skin or mucous membranes. It can thus be used in a cosmetic
treatment process for the purpose of promoting the synthesis of
ceramides and/or of improving the barrier function of the skin or
mucous membranes, comprising the application of the composition
according to the invention to the skin or mucous membranes.
[0087] The present invention also relates to a process for the
cosmetic treatment of the skin, comprising the application of the
composition according to the invention to the skin for the purpose
of maintaining the radiance of the complexion and/or of preventing
and/or treating roughness of the skin.
[0088] The present invention additionally relates to a cosmetic
process for moisturizing the skin or mucous membranes, comprising
the application of a composition according to the invention to the
skin or mucous membranes.
[0089] Another aspect of the invention relates to a process for the
cosmetic treatment of dry skin, comprising the application of a
composition according to the invention to the skin.
[0090] In an alternative form, the composition according to the
invention can be used for the manufacture of a dermatological
preparation comprising an aqueous phase which is intended to
promote the synthesis of ceramides and/or to improve the barrier
function of the skin.
[0091] The examples which follow serve to illustrate the invention
without, however, exhibiting a limiting nature. The compounds are,
depending on the situation, cited according to chemical names or
according to CTFA (International Cosmetic Ingredient Dictionary and
Handbook) names.
EXAMPLES
Example 1
[0092] Accelerated Storage Test.
[0093] The aim of this test is to study the decomposition of an
oxidation-sensitive hydrophilic active principle after storing for
two months at 45.degree. C. Various solutions were prepared and
their compositions are collated in the following table:
1TABLE I Solution A Compositions (in water) (Control) Solution B
Solution C Solution D Ascorbic acid 15% 15% 15% 15% Polymer 1 -- 1%
-- -- Polymer 2 -- -- 1% -- Polymer 3 -- -- -- 1%
[0094] All the solutions are brought to pH 6 with 8.9 mol/l
KOH.
[0095] The percentages of the polymers are given as active
material.
[0096] Polymer 1: Vinylpyrrolidone/vinylimidazole (50/50) copolymer
sold under the reference Luvitec VPI 55K72W of BASF (Weight-average
molecular mass 1.2.times.10.sup.6).
[0097] Polymer 2: Vinylpyrrolidone/vinylimidazole (50/50) copolymer
sold under the reference Luvitec VPI 55K18P of BASF (Weight-average
molecular mass 10 000).
[0098] Polymer 3: Polyvinylpyrrolidone sold under the reference
Kollidon 12PF of BASF (Weight-average molecular mass 3 000).
[0099] The degree of decomposition measured is given by the
ratio:
(C.sub.0-C.sub.2 months)/C.sub.0
[0100] with C.sub.0 concentration of ascorbic acid at t=0 and
C.sub.2 months the concentration of ascorbic acid at t=2 months,
under the conditions indicated in the above table.
[0101] The concentration of ascorbic acid is determined by the HPLC
technique (LaChrom Merck system). The analytical conditions are as
follows:
[0102] Column: Lichrosphere100 RP18 (250 mm)
[0103] Eluent: 0.1M phosphate buffer, pH 2.1
[0104] Flow rate: 1 ml/min
[0105] Detection at 257 nm
[0106] Dilution of the sample such that the concentration of
ascorbic acid is between 0.05 and 1 mg/ml.
[0107] The results obtained are collated in the following Table
II:
2 TABLE II Degree of decomposition after 2 months at 45.degree. C.
(in %) under air, amber glass under nitrogen, aluminium bottle
flask Solution A 43 19.4 Solution B 10.8 1 Solution C 23.4 4.5
Solution D 35.8 15.7
[0108] It is found, from Table II, that the stability of ascorbic
acid is improved in the presence of Polymer 1 and Polymer 2 of the
invention, even in the presence of atmospheric oxygen, in
comparison with the control. It is also found that the
N-vinylpyrrolidone homopolymer alone is not sufficient to
effectively stabilize the ascorbic acid solution.
[0109] As the polymers mentioned are hydrophilic, it will be
sufficient to add them to an aqueous ascorbic acid solution to
stabilize the ascorbic acid.
Example 2
[0110] Effect of the Composition According to the Invention on the
Differentiation of Keratinocytes
[0111] Principle of the Method:
[0112] The study consists in evaluating the effect of the
combination of ascorbic acid and of a polymer or copolymer
according to the invention on the differentiation of keratinocytes
by measuring the transglutaminase activity (TGk) of cultured human
epidermal keratinocytes. The TGk is a marker of the terminal
differentiation of the keratinocyte and of the formation of the
cornified envelope (corneocyte).
[0113] Human epidermal keratinocytes used at the 3rd passage are
inoculated in a 96-well plate at a density of 10 000 cells per well
and are cultured in complete SFM medium (Gibco 170005034, EGF and
pituitary extract). After preincubating for 24 hours, the cells are
brought into contact with the product (tested at 30 .mu.M) for 48
hours. The cells are subsequently washed and then sonicated on ice
in Tris/EDTA, pH 8 buffer. The membrane enzyme is extracted in the
presence of Triton X100. The TGk activity is quantitatively
determined by measuring the covalent addition of tritiated
putrescine to casein to a final concentration of 2 .mu.Ci/ml. The
casein is precipitated with 20% trichloroacetic acid comprising 1
mM of putrescine. The precipitates are collected on Skatron filters
and collector. The precipitates are washed in 5% TCA medium
comprising 0.1 mM of putrescine and ethanol. The dry filters are
counted by liquid scintillation. The proteins are quantitatively
determined on each sample using a Dc Protein Assay kit (BioRad).
The TGk activities are reported in .mu.g of protein.
[0114] Retinol (10.sup.-6 M) and a calcium-poor medium were used as
references for antidifferentiating effect.
[0115] Intergroup comparisons were carried out by variance analysis
(ANOVA) using Dunnett's multiple comparison test.
[0116] Results:
[0117] The results show that the combination of ascorbic acid and
of an N-vinylimidazole/N-vinylpyrrolidone copolymer leads to a
significant increase in the TGk activity present in cultures of
keratinocytes and thus to a prodifferentiating activity with
respect to the keratinocytes. Furthermore, this compound had no
cytotoxicity under the conditions of the test.
Example 3
[0118] O/W Fluid
[0119] The following composition is prepared in a way conventional
to persons skilled in the art.
3 Methyl glucose sesquistearate 2 g Stearyl alcohol and
ceteareth-20 2 g Cyclohexasiloxane 10 g Propyl paraben 0.1 g Prunus
armeniaca (apricot) kernel oil 6 g Shorea robusta seed butter 2 g
Water 13.85 g Methylparaben 0.25 g PEG-20 methyl glucose
sesquistearate 2 g Ascorbic acid 5 g Potassium hydroxide (50%
solution) 2.97 g Vinylpyrrolidone/vinylimidazole copolymer 1 g
Water 41.03 g Polyacrylamide and C.sub.13-14 isoparaffin and
Laureth-7 1 g Xanthan gum 0.25 g Chlorohexidine digluconate 0.05 g
Water 10.5 g
[0120] A soft and fresh fluid is obtained, which fluid improves the
appearance of the skin by virtue of better moisturizing and in
which fluid ascorbic acid has good stability.
Example 4
[0121] O/W Cream
[0122] The following composition is prepared in a way conventional
to a person skilled in the art.
4 Phase A: Glyceryl stearate and PEG-100 stearate 2.1 g Polysorbate
60 0.9 g Cetyl alcohol 2.6 g Hydrogenated polyisobutene 12 g
Cyclomethicone 8 g Phase B: Water 59.23 g Glycerol 2 g Ascorbic
acid 5 g Potassium hydroxide (50% solution) 3.07 g
Vinylpyrrolidone/vinylimidazole copolymer 1 g Xanthan gum 0.1 g
Carbomer 0.4 g Phase C: Triethanolamine 0.3 g Water 3 g
Preservatives 0 .3 g
[0123] A soft and fresh fluid is obtained, which fluid provides
better moisturizing and in which fluid ascorbic acid has good
stability.
[0124] The above description of the invention, as illustrated by
non-limiting examples, allows one of ordinary skill in the art to
make and use a method for promoting the synthesis of ceramides
and/or improving the barrier function of the skin with a
composition comprising, preferably in a physiologically acceptable
medium comprising an aqueous phase, at least one
oxidation-sensitive hydrophilic active principle selected from the
group consisting of ascorbic acid and its derivatives and at least
one non-crosslinked N-vinylimidazole polymer or copolymer, the said
active principle and the said polymer or copolymer both being
present in the aqueous phase by simple application to the skin of
the described composition. Also fully described in such terms as to
allow one of ordinary skill to make and use it is a method for
maintaining and/or improving the radiance of the complexion with
application of a composition comprising, preferably in a
physiologically acceptable medium comprising an aqueous phase, at
least one oxidation-sensitive hydrophilic active principle selected
from the group consisting of ascorbic acid and its derivatives and
at least one non-crosslinked N-vinylimidazole polymer or copolymer,
the said active principle and the said polymer or copolymer both
being in the aqueous phase. Similarly fully described is a method
for preventing and/or combating roughness of the skin using such a
composition. Also fully described in terms allowing one of ordinary
skill to make and use it is the use of at least one
oxidation-sensitive principle selected from the group consisting of
ascorbic acid and its derivatives and of at least one
non-crosslinked N-vinylimidazole polymer or copolymer for the
preparation of a dermatological composition comprising an aqueous
phase which is intended to promote the synthesis of ceramides
and/or to improve the barrier function of the skin, and a process
for moisturizing the skin and/or treating dry skin and/or
maintaining and/or improving the radiance of the complexion,
comprising the application to the skin of a composition comprising,
preferably in a physiologically acceptable medium, at least one
oxidation-sensitive hydrophilic active principle selected from the
group consisting of ascorbic acid and its derivatives and at least
one non-crosslinked N-vinylimidazole polymer or copolymer, the
active principle and the polymer or copolymer both being present in
the aqueous phase.
[0125] French Patent Application 0115375 is hereby incorporated by
reference, as are all documents, references, texts, patents,
applications, standards, etc. mentioned above. Where a numerical
range or limit stated herein, all values therebetween are
incorporated as if specifically written out.
[0126] Also incorporated herein by reference are the following U.S.
applications, all filed Nov. 27, 2002, where the present
application is listed for information only:
[0127] U.S. Ser. No. ______ (Atty. Docket 230634US0)
[0128] U.S. Ser. No. ______ (Atty. Docket 230608US0)
[0129] U.S. Ser. No. ______ (Atty. Docket 230616US0)
[0130] U.S. Ser. No. ______ (Atty. Docket 230614US0)
[0131] U.S. Ser. No. ______ (Atty. Docket 230615US0)
* * * * *